哑巴新娘
2026年度百校千团“冀企行”在石家庄启动 242个高校科研团队将深入企业靶向攻关_我的网站
一 | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。 日报讯（记者王璐丹）近日，2026年度百校千团“冀企行”暨高校科技特派团服务活动在石家庄启动。作为全省首站，本次活动征集企业技术需求100余项，来自40所高校的242个科研团队深入企业一线开展服务。百校千团“冀企行”是省教育厅推动高校深化改革、开放办学、服务发展的重要抓手，是推进教育、科技、人才一体化发展的重要载体，旨在组织高校科研团队对接企业技术攻关与成果转化需求，为企业纾困解难、为产业提质赋能。活动现场，省教育厅发布了“高校人才应用场景”，遴选出40所高校242个科研团队的数千名专家学者，整合各类专利成果700余项、软件著作权100余项，分领域发布新一代电子信息110个场景、生物医药74个场景、数字经济58个场景。
二 | 石家庄市科学技术局发布了北京（京津冀）国际科技创新中心石家庄重要支点城市的“四张清单”，围绕“验证+中试+场景”资源及企业技术需求进行推介。
三 | 为促进校企精准对接，活动围绕新一代电子信息、生物医药、数字经济三大主导产业，开展了优质创新项目专场路演，入选项目将纳入产学研项目储备库。活动还同步开展了青年教师校企合作实操能力提升培训，围绕企业需求挖掘、科研人员权益保护等内容进行专题授课。“本次活动是京津冀科教资源联动、产学研精准对接的生动实践，为京津冀高校科创资源与石家庄产业需求搭建了高效对接平台。”省教育厅相关负责人表示，他们将以此次活动为契机，持续深化京津冀产学研协同，精准对接企业技术攻关与人才引育需求，推动更多京津优质科创项目落地实施。
四 |
Current article:http://h3efwk3.rangnehongranlinren.bond/6dhw2/20260826/9905.html
Published on:07:35:48